DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS ⚠️ Early Stage / Preclinical Research
The NUS team engineered LEAF, a nanosized thylakoid-derived particle that produces NADPH when exposed to ambient light, interrupting the ROS-driven inflammatory cycle that underlies dry eye disease. In two preclinical trials, LEAF administered as eye drops outperformed cyclosporine A and reversed corneal damage to near-healthy levels within five days, with no adverse effects observed over two months of safety assessment.
Clinical Considerations
- LEAF restored NADPH levels within 30 minutes of light exposure in inflamed cell models and shifted corneal immune cells from pro- to anti-inflammatory states
- In dry eye patient tear samples ex vivo, LEAF increased NADPH roughly 20-fold and reduced hydrogen peroxide by more than 95%
- Doses were low enough to avoid interference with color perception; safety studies showed no skin sensitization, eye irritation, or organ toxicity over two months
- No human clinical trials have been conducted; translation to patients remains unvalidated
Practice Applications
- Recognize LEAF as a biologically novel mechanism distinct from cyclosporine A and lifitegrast, targeting NADPH restoration rather than specific inflammatory pathway inhibition
- Interpret preclinical outperformance of Restasis cautiously: animal model results frequently do not replicate in human trials
- Monitor for clinical trial initiation as the next meaningful evidence threshold for this technology
